Your shopping cart is empty!
U.S. FDA Approves Symdeko (ivacaftor/tezacaftor and ivacaftor) Tablets For The Treatment Of Cystic Fibrosis
- Hits: 247
U.S. FDA approves Symdeko (ivacaftor/tezacaftor and ivacaftor) Tablets for the treatment of Cystic Fibrosis
Vertex Pharmaceuticals receives FDA approval for Symdeko (ivacaftor/tezacaftor and ivacaftor) tablets for the treatment of Cystic Fibrosis
Company: Vertex Pharmaceuticals Incorporated
Brand Name: Symdeko
Generic Name: ivacaftor/tezacaftor and ivacaftor
Treatment For: Cystic Fibrosis
General information about Symdeko
Symdeko (ivacaftor/tezacaftor tablets and ivacaftor tablets) is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator and CFTR corrector combination for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have two copies of the F508del mutation, or who have at least one mutation in the CF gene that is responsive to treatment with Symdeko.